Journal
ALZHEIMERS RESEARCH & THERAPY
Volume 15, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13195-023-01227-4
Keywords
Therapeutic trials; Alzheimer's disease; Digital tools; Decentralized trials
Categories
Ask authors/readers for more resources
Decentralized clinical trials (DCTs) have the potential to overcome screening and recruitment challenges in Alzheimer's disease (AD) therapeutic trials, and may facilitate involvement of primary care providers and caregivers. However, further research is needed to assess the feasibility of DCTs in AD.
BackgroundTherapeutic trials in Alzheimer's disease (AD) face many obstacles-particularly with regard to screening and recruitment.DiscussionDecentralized clinical trials (DCTs) are being developed in other diseases and appear to be of value for overcoming these difficulties. The use of remote visits offers hope of broader recruitment and thus a reduction in inequalities due to age, geography, and ethnicity. Furthermore, it might be easier to involve primary care providers and caregivers in DCTs. However, further studies are needed to determine the feasibility of DCTs in AD.A mixed-model DCT might constitute the first step towards completely remote trials in AD and should be assessed first.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available